Treatment of scleroderma.

Abstract

Article1 February 1959TREATMENT OF SCLERODERMACHRIS J. D. ZARAFONETIS, M.D., F.A.C.P.CHRIS J. D. ZARAFONETIS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-50-2-343 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptScleroderma, or diffuse systemic sclerosis, is a challenging disease. Its etiology is not known and its pathogenesis is poorly understood. The clinical and histopathologic features of scleroderma, however, have been repeatedly described1, 2, 3and need be mentioned only briefly here. Characteristically there is cutaneous involvement, usually ushered in by an acute edematous phase, followed by induration and then atrophy. Raynaud's phenomenon may precede, accompany or, rarely, follow the onset of objective skin change. Pain and stiffness of joints, and myalgias are not uncommon. Although the changes in the skin may dominate the clinical picture, it is now well known...Bibliography1. Goetz RH: The pathology of progressive systemic sclerosis (generalized scleroderma) with special reference to changes in the viscera, Clin. Proc. 4: 337-392, 1945. Google Scholar2. LindsayTempletonRothman JRFES: Lesions of the esophagus in generalized progressive scleroderma, J. A. M. A. 123: 745-750, 1943. CrossrefGoogle Scholar3. LeinwandDuryeeRichter IAWMN: Scleroderma (based on a study of over 150 cases), Ann. Int. Med. 41: 1003-1041, 1954. LinkGoogle Scholar4. Zarafonetis CJ: Therapeutic possibilities of para-aminobenzoic acid, Ann. Int. Med. 30: 1188-1211, 1949. LinkGoogle Scholar5. ZarafonetisCurtisGulick CJACAE: Use of para-aminobenzoic acid in dermatomyositis and scleroderma, Arch. Int. Med. 85: 27-43, 1950. CrossrefGoogle Scholar6. Zarafonetis CJ: Clinical use of para-aminobenzoic acid, Texas State J. Med. 49: 666-672, 1953. MedlineGoogle Scholar7. RodmanSchreinerBlack GPGERI: Renal involvement in progressive systemic sclerosis (generalized scleroderma), Am. J. Med. 23: 445-462, 1957. CrossrefMedlineGoogle Scholar8. LorberZarafonetis SHCJ: Esophageal transport studies in patients with scleroderma, to be published. Google Scholar9. Zarafonetis CJ: Treatment of pemphigus with potassium para-aminobenzoate, Am. J. M. Sc. 231: 30-50, 1956. CrossrefMedlineGoogle Scholar10. ZarafonetisLorberHansons CJSHSM: Association of functioning carcinoid syndrome and scleroderma. I. Case report, Am. J. M. Sc. 236: 1-14, 1958. CrossrefMedlineGoogle Scholar11. ZarafonetisKalasWatts CJJPHM: Association of functioning carcinoid syndrome and scleroderma. II. Possible clue to pathogenesis of scleroderma and fibrosis in general, to be published. Google Scholar12. Greiff D: Biology of the Rickettsiae , in The rickettsial diseases of man, 1948, American Association for the Advancement of Science, Washington, D. C., pp. 51-53. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Philadelphia, Pennsylvania*Presented as a Morning Lecture at the Thirty-ninth Annual Session of The American College of Physicians, Atlantic City, New Jersey, April 29, 1958.From the Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania.Requests for reprints should be addressed to Chris J. D. Zarafonetis, M.D., Professor of Clinical and Research Medicine, Temple University Medical Center, Philadelphia 40, Pennsylvania. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTreatment of Generalized Systemic SclerosisTreatment of systemic sclerosis in 1988Skin Fibroblast Monolayers: A Suitable Case for Treatment?Effects of Potassium Para-aminobenzoate on Growth and Macromolecule Synthesis in Fibroblasts Cultured from Normal and Selerodermatous Human Skin, and Rheumatoid Synovial CellsMotor Disorders Due to Collagen Diseaseshigh-performance liquid chromatographic method for the determination ofp-aminobenzoic acid and some of its metabolitesCarcinoid — its TreatmentPathophysiology of Scleroderma-A ReviewDecreased oxidative deamination of catecholamines associated with clinical sclerodermaPolymyositisFunctional and morphologic alterations of the gastrointestinal tract in progressive systemic sclerosis (scleroderma)Results of Pharmacologic Treatment in the Malignant Carcinoid SyndromeRheumatism and Arthritis Review of American and English Literature of Recent Years (Fourteenth Rheumatism Review)CHARLEY J. SMYTH, M.D., F.A.C.P., ROGER L. BLACK, M.D., CHARLES L. CHRISTIAN, M.D., EPHRAIM P. ENGLEMAN, M.D., F.A.C.P., EDWARD C. FRANKLIN, M.D., DONALD F. HILL, M.D., F.A.C.P., JOSEPH L. HOLLANDER, M.D., F.A.C.P., HOWARD L. HOLLEY, M.D., F.A.C.P., JOHN G. MAYNE, M.D., WILLIAM M. MIKKELSEN, M.D., CHARLES L. SHORT, M.D., F.A.C.P., HUGH A. SMYTHE, M.D., F.R.C.P.(C), OTTO STEINBROCKER, M.D., HOWARD J. WEINBERGER, M.D.Progressive Systemic Sclerosis (Scleroderma)Focal sclerodermaScleroderma Treated With Steroids Through Pregnancy, Cesarean Section and PuerperiumReticulum cell sarcoma complicating atopic dermatitis.Prolonged remission following potaba therapySclerodermaSpecial Issue: Significance of Tissue Chromaffin Cells and Mast Cells in ManRENAL INVOLVEMENT IN SCLERODERMA*E. C. KHOO, M.D., THOMAS A. STUMP, M.D.Urinary Indoles and other "Ehrlich's Reagent Reactors" in Rheumatoid ArthritisTreatment of Peyronie’s Disease With Potassium Para-Aminobenzoate (potaba) 1 February 1959Volume 50, Issue 2Page: 343-365KeywordsDysphagiaFibrosisMyalgiaPathogenesisRaynaud syndromeRespirationSclerodermaStiffnessSystemic diseasesThorax ePublished: 1 December 2008 Issue Published: 1 February 1959 PDF downloadLoading ...